Getting back on the road towards tuberculosis elimination: lessons learnt from the COVID-19 pandemic

Furtado, Isabel; Aguiar, Ana; Duarte, Raquel

doi:10.36416/1806-3756/e20210123

Cited by 4 publications

(2 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 1 , 2 , 3 The functioning and response of many health services, including tuberculosis (TB) services, were profoundly affected by the policies adopted to respond to the pandemic, such as country lockdowns, reallocation of health professionals, materials, and diagnostic tools, and reduction of outpatient care. 4 , 5 , 6 , 7 , 8…”

Section: Introductionmentioning

confidence: 99%

Impact of the COVID-19 pandemic on tuberculosis services

et al. 2022

Self Cite

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Impact of the COVID-19 pandemic on tuberculosis services

et al. 2022

Self Cite

View full text Add to dashboard Cite

“…COVID-19 pandemic has shown a significant disruptive impact on Tuberculosis (TB) services, with negative effects on prompt diagnosis, treatment and immunization. 1 , 2 Pressure on laboratories and pharmaceutical industries led to the readaptation of many TB labs to detect SARS-CoV-2 as well as Bacillus Calmette-Guérin (BCG) shortages and consequent decrease of newborn vaccinations. 3 Estimates indicate a 25% drop in the global BCG coverage and an increase in pediatric deaths ranging from 0.5% to 17%.…”

Section: Introductionmentioning

confidence: 99%

The Dark Side of the Covid-19 Treatments on Mycobacterium Tuberculosis Infection

Maio

Bianco

Delogu

2022

Mediterr J Hematol Infect Dis

View full text Add to dashboard Cite

Since the emergence of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) at the end of 2019, a number of medications have been used to treat the infection and the related Coronavirus disease – 19 (COVID-19). Some of the administered drugs were tested or used in practice only on the basis of biological plausibility; a promising strategy was to target the host immune response, with host directed therapies (HDTs), to reduce systemic hyperinflammation and hypercytokinemia responsible for additional tissue damage. We summarize the treatments against SARS-CoV-2 and underline their possible effects on Mycobacterium tuberculosis (Mtb) infection. Both SARS-CoV-2 and Mtb respiratory infections impair the host’s immune response. Furthermore, little research has been conducted on the impact of medicaments used to counteract COVID-19 disease in patients with Latent Tuberculosis Infection (LTBI). A number of these drugs may modulate host immune response by modifying LTBI dynamic equilibrium, favoring either the host or the bacteria. Keywords: SARS-CoV-2, Mycobacterium tuberculosis, COVID-19, Tuberculosis, Host directed therapies

show abstract

The burden of COVID-19 pandemic on tuberculosis detection: a single-center study

et al. 2022

View full text Add to dashboard Cite

Background Since being declared a global pandemic, Coronavirus disease 2019 (COVID-19) took over healthcare providers and researchers’ interest. However, other epidemic diseases, including tuberculosis (TB), are still a health issue that aggravate under the umbrella of health facilities exhaustion. This study aims to evaluate the impact of the COVID-19 pandemic on tuberculosis management. Methods A retrospective analysis of the quarterly reports issued by a tuberculosis management unit from 2017 to June 2021, including data of 12 subunits. The changes in pulmonary and extrapulmonary tuberculosis incidence trends (new + relapsed cases) throughout the 4 years were reported. The quarterly changed percentages in cases numbers along 2020 and first half of 2021 was compared with that of the same periods in 2019. Results Incidence of extrapulmonary tuberculosis was higher than pulmonary tuberculosis throughout the 4 year study periods (7.69 vs. 4.49, 9.44 vs. 4.33, 7.75 vs. 3.58, and 7.82 vs. 2.94/100.000 population, respectively) with a noticeable decline in the incidence of pulmonary TB during 2020. The second quarter of 2020 showed the lowest tuberculosis incidence rate with a 41.6% decline in the total number of diagnosed cases while 2nd quarter of 2021 showed 21.2% decline. During 2020, only 4 cases of multidrug-resistant TB were reported (compared to an average of 8 cases of MDR-TB yearly before the COVID-19 era). Conclusion There was a noticeable drop in tuberculosis case detection during the COVID-19 pandemic. The lockdown, started in Egypt by the end of March 2020, could contribute to the marked drop in the second quarter. However, a steady partial decline was continued during the first half of 2021, which foretells a growing problem.

show abstract

Getting back on the road towards tuberculosis elimination: lessons learnt from the COVID-19 pandemic

Cited by 4 publications

References 9 publications

Impact of the COVID-19 pandemic on tuberculosis services

Impact of the COVID-19 pandemic on tuberculosis services

The Dark Side of the Covid-19 Treatments on Mycobacterium Tuberculosis Infection

The burden of COVID-19 pandemic on tuberculosis detection: a single-center study

Contact Info

Product

Resources

About